The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors

Current Gastroenterology Reports

Volumn 19, Issue 8, 2017, Pages

  Minalyan, Artem ^a   Gabrielyan, Lilit ^a,b   Scott, David ^a   Jacobs, Jonathan ^a   Pisegna, Joseph R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Gastrointestinal tract; Helicobacter pylori; Microbiome; Microbiota; Proton pump inhibitors (PPIs)

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR; RNA 16S;

ACTINOBACTERIA; BACTERIUM COLONY; BACTEROIDETES; CYANOBACTERIUM; FIRMICUTES; FUSOBACTERIA; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; MICROBIAL DIVERSITY; NONHUMAN; PROTEOBACTERIA; REVIEW; RNA SEQUENCE; STOMACH ACID SECRETION; STOMACH PH; VERRUCOMICROBIA; DRUG EFFECTS; GASTRITIS; GENETICS; MICROBIOLOGY; PATHOGENICITY; PEPTIC ULCER; SECRETION (PROCESS); STOMACH ACID; STREPTOCOCCUS;

GASTRIC ACID; GASTRITIS; GASTROINTESTINAL MICROBIOME; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; RNA, RIBOSOMAL, 16S; STREPTOCOCCUS;

EID: 85025434230     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-017-0577-6     Document Type: Review

References (126)

1. Ramsay PT, Carr A. Gastric acid and digestive physiology. Surg Clin North Am. 2011;91(5):977–82.
2. Zeng N, Athmann C, Kang T, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest. 1999;104(10):1383–91.
3. Yamaji N, Yokoo Y, Iwashita T, et al. Structural determination of two active compounds that bind to the muscarinic M3 receptor in beer. Alcohol Clin Exp Res. 2007;31:S9–S14.
4. Schubert ML, Makhlouf GM. Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology. 1993;104(3):834–9.
5. Orloff SL, Bunnett NW, Wong H, Walsh JH, Debas HT. Neural and hormonal mechanisms mediate the enterogastric reflex: a study in intestinal transplants in rats. Gastroenterology. 1991;101(3):734–42.
6. Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol. 2015;13(4):386–97.
7. Schubert ML. Gastric acid secretion. Curr Opin Gastroenterol. 2016;32(6):452–60.
8. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60.
9. Takeuchi K, Endoh T, Hayashi S, Aihara T. Activation of muscarinic acetylcholine receptor subtype 4 is essential for cholinergic stimulation of gastric acid secretion: relation to D cell/somatostatin. Front Pharmacol. 2016;7:278.
10. Frick C, Rettenberger AT, Lunz ML, Breer H. Complex morphology of gastrin-releasing G-cells in the antral region of the mouse stomach. Cell Tissue Res. 2016;366(2):301–10.
11. Bitziou E, Patel BA. Simultaneous detection of gastric acid and histamine release to unravel the regulation of acid secretion from the guinea pig stomach. Am J Physiol Gastrointest Liver Physiol. 2012;303(3):G396–403.
12. Vuyyuru L, Schubert ML. Histamine, acting via H3 receptors, inhibits somatostatin and stimulates acid secretion in isolated mouse stomach. Gastroenterology. 1997;113(5):1545–52.
13. Schubert ML, Hightower J, Makhlouf GM. Linkage between somatostatin and acid secretion: evidence from use of pertussis toxin. Am J Phys. 1989;256(2 Pt 1):G418–22.
14. Beales ILP. Regulation of gastric function by gastrin releasing peptide. Gut. 2002;50(6):897–8.
15. Yakabi K, Kawashima J, Kato S. Ghrelin and gastric acid secretion. World J Gastroenterol. 2008;14(41):6334–8.
16. Shimizu K, Li P, Lee KY, Chang TM, Chey WY. The mechanism of inhibitory action of secretin on gastric acid secretion in conscious rats. J Physiol. 1995;488(Pt 2):501–8.
17. Schmidt WE, Schenk S, Nustede R, Holst JJ, Folsch UR, Creutzfeldt W. Cholecystokinin is a negative regulator of gastric acid secretion and postprandial release of gastrin in humans. Gastroenterology. 1994;107(6):1610–20.
18. Konturek JW, Konturek SJ, Kwiecien N, et al. Leptin in the control of gastric secretion and gut hormones in humans infected with Helicobacter pylori. Scand J Gastroenterol. 2001;36(11):1148–54.
19. Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Archiv. 2009;457(3):609–22.
20. Caplan MJ. The future of the pump. J Clin Gastroenterol. 2007;41(Suppl 2):S217–22.
21. Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev. 1995;75(1):155–89.
22. Fujii T, Fujita K, Takeguchi N, Sakai H. Function of K(+)-Cl(−) cotransporters in the acid secretory mechanism of gastric parietal cells. Biol Pharm Bull. 2011;34(6):810–2.
23. Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase. Nature. 1981;290(5802):159–61.
24. Li H, Meng L, Liu F, Wei JF, Wang YQ. H+/K+-ATPase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(1):99–111.
25. Galmiche JP, Bruley Des Varannes S, Ducrotte P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther. 2004;19(6):655–62.
26. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.
27. Sachs G, Shin JM. The basis of differentiation of PPIs. Drugs Today (Barc). 2004;40(Suppl A):9–14.
28. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002;123(5):1588–97.
29. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(8):963–78.
30. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267–72.
31. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther. 2000;14(8):1049–56.
32. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36.
33. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28(8):966–72.
34. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(7):523–37.
35. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027–30.
36. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PloS One. 2013;8(4):e62162.
37. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.
38. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97.
39. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014;19:1–5.
40. McJunkin B, Sissoko M, Levien J, Upchurch J, Ahmed A. Dramatic decline in prevalence of Helicobacter pylori and peptic ulcer disease in an endoscopy-referral population. Am J Med. 124(3):260–4.
41. Segal I, Ally R, Mitchell H. Helicobacter pylori—an African perspective. QJM: Int J Med. 2001;94(10):561–5.
42. Cave DR. How is Helicobacter pylori transmitted? Gastroenterology. 1997;113(6 Suppl):S9–14.
43. van Duynhoven YT, de Jonge R. Transmission of Helicobacter pylori: a role for food? Bull World Health Organ. 2001;79(5):455–60.
44. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006;103(3):732–7.
45. Blaser MJ. Helicobacter pylori: microbiology of a ‘slow’ bacterial infection. Trends Microbiol. 1993;1(7):255–60.
46. Stingl K, Altendorf K, Bakker EP. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis? Trends Microbiol. 2002;10(2):70–4.
47. Kao C-Y, Sheu B-S, Wu J-J. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biom J. 2016;39(1):14–23.
48. Logan RP. Adherence of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10(Suppl 1):3–15.
49. Bytzer P, Dahlerup JF, Eriksen JR, Jarbol DE, Rosenstock S, Wildt S. Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull. 2011;58(4):C4271.
50. McColl KE, El-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull. 1998;54(1):121–38.
51. Chen XY, Liu WZ, Shi Y, Zhang DZ, Xiao SD, Tytgat GNJ. Helicobacter pylori associated gastric diseases and lymphoid tissue hyperplasia in gastric antral mucosa. J Clin Pathol. 2002;55(2):133–7.
52. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991;324(15):1043–8.
53. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ. 1999;319(7216):1040–4.
54. Kim SS, Ruiz VE, Carroll JD, Moss SF. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett. 2011;305(2):228–38.
55. Gasbarrini A, Carloni E, Gasbarrini G, Chisholm SA. Helicobacter pylori and extragastric diseases—other Helicobacters. Helicobacter. 2004;9:57–66.
56. Shahabi S, Rasmi Y, Jazani NH, Hassan ZM. Protective effects of Helicobacter pylori against gastroesophageal reflux disease may be due to a neuroimmunological anti-inflammatory mechanism. Immunol Cell Biol. 2007;86(2):175–8.
57. Amedei A, Codolo G, Del Prete G, de Bernard M, D’Elios MM. The effect of Helicobacter pylori on asthma and allergy. J Asthma Allergy. 2010;3:139–47.
58. Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med. 2015;3(1):10.
59. Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol: WJG. 2014;20(36):12781–808.
60. Li C, Ha T, Ferguson DA Jr, et al. A newly developed PCR assay of H. pylori in gastric biopsy, saliva, and feces. Evidence of high prevalence of H. pylori in saliva supports oral transmission. Dig Dis Sci. 1996;41(11):2142–9.
61. Liu H, Rahman A, Semino-Mora C, Doi SQ, Dubois A. Specific and sensitive detection of H. pylori in biological specimens by real-time RT-PCR and in situ hybridization. PloS One. 2008;3(7):e2689.
62. Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio. 2015;6(2):e00037.
63. Jovel J, Patterson J, Wang W, et al. Characterization of the gut microbiome using 16S or shotgun metagenomics. Front Microbiol. 2016;7:459.
64. Li X-X, Wong GL-H, To K-F, et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One. 2009;4(11):e7985.
65. • Khosravi Y, Dieye Y, Poh BH, et al. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients. Sci World J. 2014;2014:610421. This study showed the correlation between Streptococcus and peptic ulcer disease. Burkholderia pseudomallei was also isolated from the gastric samples, suggesting geographical variations in the biodiversity of gastric microbiome.
66. Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202.
67. Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):39–45.
68. Delgado S, Cabrera-Rubio R, Mira A, Suarez A, Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol. 2013;65(3):763–72.
69. •• Rolig AS, Cech C, Ahler E, Carter JE, Ottemann KM. The degree of Helicobacter pylori-triggered inflammation is manipulated by preinfection host microbiota. Infect Immun. 2013;81(5):1382–9. The authors revealed that the clinical course and outcome of H. pylori disease are influenced by the host gastric bacterial composition. They suggested that gastric microbiome could be used as a diagnostic marker to predict the outcome of H. pylori infection.
70. Delgado S, Leite AM, Ruas-Madiedo P, Mayo B. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2014;5:766.
71. Khosravi Y, Dieye Y, Loke MF, Goh KL, Vadivelu J. Streptococcus mitis induces conversion of Helicobacter pylori to coccoid cells during co-culture in vitro. PLoS One. 2014;9(11):e112214.
72. Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One. 2008;3(7):e2836.
73. Brawner KM, Kumar R, Serrano CA, et al. Helicobacter pylori infection is associated with an altered gastric microbiota in children. Mucosal Immunol. 2017;
74. Llorca L, Perez-Perez G, Urruzuno P, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status. Pediatr Infect Dis J. 2017;36(2):173–8.
75. Nardone G, Compare D. The human gastric microbiota: is it time to rethink the pathogenesis of stomach diseases? United European Gastroenterol J. 2015;3(3):255–60.
76. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993;88(10):1801–2.
77. Stoschus B, Dominguez-Munoz JE, Kalhori N, Sauerbruch T, Malfertheiner P. Effect of omeprazole on Helicobacter pylori urease activity in vivo. Eur J Gastroenterol Hepatol. 1996;8(8):811–3.
78. Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.
79. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.
80. •• Paroni Sterbini F, Palladini A, Masucci L, et al. Effects of proton pump inhibitors on the gastric mucosa-associated microbiota in dyspeptic patients. Appl Environm Microbiol. 2016;82(22):6633–44. Firmicutes, particularly the Streptococcus genus, were found in a relative abundance in patients taking PPIs. The authors suggested that it may explain the exacerbation and persistence of dyspeptic symptoms in patients on PPI therapy.
81. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48.
82. Mandar R, Mikelsaar M. Transmission of mother’s microflora to the newborn at birth. Biol Neonate. 1996;69(1):30–5.
83. Neu J, Rushing J. Cesarean versus vaginal delivery: long term infant outcomes and the hygiene hypothesis. Clin Perinatol. 2011;38(2):321–31.
84. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7.
85. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688–93.
86. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–76.
87. Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within? Infect Immun. 2008;76(8):3360–73.
88. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol. 2007;3(2):112–22.
89. Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11(8):1131–40.
90. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–8.
91. Kahrstrom CT, Pariente N, Weiss U. Intestinal microbiota in health and disease. Nature. 2016;535(7610):47–7.
92. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.
93. Al-Asmakh M, Hedin L. Microbiota and the control of blood-tissue barriers. Tissue Barriers. 2015;3(3):e1039691.
94. Smith P, Willemsen D, Popkes ML, et al. Regulation of life span by the gut microbiota in the short-lived African turquoise killifish. bioRxiv. 2017;
95. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26 doi:10.3402/mehd.v3426.26191.
96. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010;156(Pt 11):3205–15.
97. Vogtmann E, Hua X, Zeller G, et al. Colorectal cancer and the human gut microbiome: reproducibility with whole-genome shotgun sequencing. PLoS One. 2016;11(5):e0155362.
98. De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10:63.
99. Tang WHW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–11.
100. Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015;17(5):592–602.
101. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-microbiota-brain axis and effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):984–95.
102. Lutgendorff F, Akkermans LM, Soderholm JD. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med. 2008;8(4):282–98.
103. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132(4):1359–74.
104. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002;99(24):15451–5.
105. Gordon HA, Bruckner-Kardoss E. Effect of normal microbial flora on intestinal surface area. Am J Phys. 1961;201:175–8.
106. Wostmann B, Bruckner-Kardoss E. Development of cecal distention in germ-free baby rats. Am J Phys. 1959;197:1345–6.
107. Husebye E, Hellstrom PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci. 1994;39(5):946–56.
108. Alam M, Midtvedt T, Uribe A. Differential cell kinetics in the ileum and colon of germfree rats. Scand J Gastroenterol. 1994;29(5):445–51.
109. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115–8.
110. Beasley DE, Koltz AM, Lambert JE, Fierer N, Dunn RR. The evolution of stomach acidity and its relevance to the human microbiome. PLoS One. 2015;10(7):e0134116.
111. Roggenbuck M, Baerholm Schnell I, Blom N, et al. The microbiome of new world vultures. Nat Commun. 2014;5:5498.
112. Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260–8.
113. Jump RLP. Clostridium difficile infection in older adults. Aging Health. 2013;9(4):403–14.
114. Russell TL, Berardi RR, Barnett JL, et al. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm Res. 1993;10(2):187–96.
115. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.
116. Lee C, Hong SN. Does long-term proton pump inhibitor therapy affect the health of gut microbiota? Gut Liver. 2016;10(6):865–6.
117. Shin CM, Kim N, Kim YS, et al. Impact of long-term proton pump inhibitor therapy on gut microbiota in F344 rats: pilot study. Gut Liver. 2016;10(6):896–901.
118. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56. quiz 2057
119. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(Suppl 2):S10–6.
120. •• Jackson MA, Goodrich JK, Maxan M-E, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56. It is a large study (1827 healthy twins) that showed negative correlation between PPI use and microbial diversity of the gut. Also, overrepresentation of the upper gastrointestinal tract bacteria in the lower parts of the gut was detected.
121. Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5. e889
122. •• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8. The findings of this European study involving both healthy subjects and patients with GI disease (1815 participants) supported the idea that PPI use is associated with the development of less healthy gut microbiome. Of note, a significant increase in pathogenic bacteria has been revealed.
123. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.
124. Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol: WJG. 2015;21(22):6817–9.
125. Lué A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: balancing risks and benefits. World J Gastroenterol. 2016;22(48):10477–81.
126. Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol. 2016;22(32):7186–202.